Chitosan Catechol Coated Injection Needle for Bleed-Free Injections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional hemostatic and adhesive products, such as cyanoacrylate-based adhesives and fibrin glue, do not adequately address adhesive strength, long-lasting properties, low toxicity, and in vivo immune responses, limiting their effectiveness and biocompatibility for surgical applications, while chitosan's low solubility in neutral solutions further restricts its medical use.
Innovation Solution
A hemostatic injection needle coated with a hydrogel comprising chitosan to which a catechol group and an oxidized catechol group are introduced and cross-linked, enhancing solubility and adhesion properties, preventing bleeding during and after injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If conventional hemostatic agents and adhesives (cyanoacrylate-based adhesives, fibrin glue) are used, then adhesive strength is achieved, but toxicity and immune response issues arise
Solution Approach 1:
The invention uses a composite material system consisting of chitosan as the base polymer, catechol groups for adhesion enhancement, and crosslinking agents (genipin or glutaraldehyde) to create a multi-functional coating that provides both adhesive strength and biocompatibility, eliminating the toxicity issues of conventional adhesives
Solution Approach 2:
The invention modifies the chemical parameters of chitosan by introducing catechol groups and applying crosslinking treatments, which fundamentally changes the material properties to achieve both strong adhesion and low toxicity, transforming chitosan from a limited medical material into an effective hemostatic agent
2Reliability
If chitosan is used for hemostatic applications, then hemostatic ability is achieved, but solubility in neutral solutions is significantly limited
Solution Approach 1:
The invention changes the chemical parameters of chitosan by introducing catechol groups and applying crosslinking modifications, which improve solubility in neutral solutions while preserving the hemostatic ability, thereby expanding the适用范围 of chitosan in medical applications
3Adaptability or versatility
If catechol group-coupled chitosan is used for adhesion, then solubility and adhesion are improved, but long-lasting properties and low toxicity are not fully satisfied
Solution Approach 1:
The invention creates a composite material system where catechol group-coupled chitosan is combined with crosslinking agents to form a crosslinked network structure, which provides both the solubility and adhesion benefits of catechol groups while adding long-lasting properties through crosslinking and reducing toxicity through biocompatible material selection
Solution Approach 2:
The invention merges multiple functional components (chitosan, catechol groups, and crosslinking agents) into a single integrated coating system that simultaneously provides solubility, adhesion, long-lasting properties, and low toxicity, achieving all required properties in one material system
4Object-affected harmful factors
If injection needle is coated with hemostatic material, then bleeding suppression is achieved, but adhesive strength and long-lasting properties are not satisfied
Solution Approach 1:
The invention uses a composite coating material on the injection needle that combines chitosan, catechol groups, and crosslinking agents, which provides both immediate bleeding suppression and long-lasting adhesive properties, overcoming the limitations of conventional hemostatic coatings
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The coated needle effectively suppresses bleeding by converting the hydrogel coating into a sealant upon contact with tissue, demonstrating improved adhesive strength, long-lasting properties, and reduced toxicity, making it suitable for various medical procedures including those with patients having low hemostatic ability or immune responses.
Implementation Method 1
a chitosan, in which a catechol group and an oxidized catechol group are introduced and cross-linked
Implementation Method 2
a chitosan, in which a catechol group and an oxidized catechol group are introduced and cross-linked
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a bleed-free injection needle coated with crosslinked chitosan having an introduced catechol group and oxidized catechol group, and the bleed-free injection needle according to the present invention is advantageous in that said needle can suppress the bleeding that occurs during an injection and hence can beneficially be used not only in patients having reduced hemostatic capacity such as diabetic patients, anticancer therapy patients and haemophilia patients but also in patients exhibiting blood rejection reactions and in injections to children as well.